ICLR

ICON PLC

Add to Watchlist

Advanced Chart

184.730

-4.93(-2.599%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

188.045

Open

187.740

VWAP

Vol

355.73K

Mkt Cap

14.75B

Low

183.590

Amount

EV/EBITDA(TTM)

11.46

Total Shares

82.78M

17.77B

EV/OCF(TTM)

15.38

P/S(TTM)

1.91

ICON Public Limited Company is a healthcare intelligence and clinical research organization. The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. It offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The Company's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. It also provides its full range of clinical, consulting and commercial services across several sectors, which include biosimilars, biotechnology, government and public health solutions, medical devices and pharmaceuticals.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

2.02B

+0.82%

3.422

+7.27%

2.02B

-1.19%

3.529

+2.89%

2.00B

-1.6%

3.334

-0.48%

Estimates Revision

The market is revising Downward the revenue expectations for ICON Public Limited Company (ICLR) for FY2025, with the revenue forecasts being adjusted by -3.14% over the past three months. During the same period, the stock price has changed by 23.72%.

Revenue Estimates for FY2025

Revise Downward

-3.14%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-2.73%

In Past 3 Month

Stock Price

Go Up

+23.72%

In Past 3 Month

13 Analyst Rating

-12.20% Downside

Wall Street analysts forecast ICLR stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ICLR is 162.20 USD with a low forecast of 144.00 USD and a high forecast of 187.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

5 Hold

0 Sell

Moderate Buy

-12.20% Downside

Current: 184.730

Low

144.00

Averages

162.20

High

187.00

-12.20% Downside

Current: 184.730

Low

144.00

Averages

162.20

High

187.00

Barclays

Equal Weight

maintain

$155 -> $180

2025-07-25

New

Reason

Barclays

Price Target

$155 -> $180

2025-07-25

New

maintain

Equal Weight

Reason

Barclays raised the firm's price target on Icon to $180 from $155 and keeps an Equal Weight rating on the shares post the Q2 report. The firm sees early signs of stabilization but says one quarter does not make a trend.

UBS

NULL -> Buy

upgrade

$170 -> $240

2025-07-25

New

Reason

UBS

Price Target

$170 -> $240

2025-07-25

New

upgrade

NULL -> Buy

Reason

UBS raised the firm's price target on Icon to $240 from $170 and keeps a Buy rating on the shares.

Mizuho

Outperform

upgrade

$173 -> $225

2025-07-25

New

Reason

Mizuho

Price Target

$173 -> $225

2025-07-25

New

upgrade

Outperform

Reason

Mizuho raised the firm's price target on Icon to $225 from $173 and keeps an Outperform rating on the shares. The company's booking trends were stable in the quarter, much better than feared, the analyst tells investors in a research note. The firm says that when coupled with improved cancelation rates and an improvement in trial delays, there is increased earnings visibility for 2026.

Baird

Neutral -> Outperform

upgrade

$150 -> $224

2025-07-24

New

Reason

Baird

Price Target

$150 -> $224

2025-07-24

New

upgrade

Neutral -> Outperform

Reason

Baird upgraded Icon to Outperform from Neutral with a price target of $224, up from $150. The firm has increased confidence in the shares after the four leading contract research originations posted sequential bookings improvement and stabilized backlog burn. It now sees a "moderate, ratable" recovery into 2026 for Icon.

Leerink

Outperform

upgrade

$195 -> $240

2025-07-24

New

Reason

Leerink

Price Target

$195 -> $240

2025-07-24

New

upgrade

Outperform

Reason

Leerink raised the firm's price target on Icon to $240 from $195 and keeps an Outperform rating on the shares. The company reported strong gross bookings wins in the quarter, the analyst tells investors in a research note. The firm sees potential for more volatility amid a choppy market but believes Icon's earnings power is solid.

Evercore ISI

Outperform

maintain

$170 -> $240

2025-07-24

New

Reason

Evercore ISI

Price Target

$170 -> $240

2025-07-24

New

maintain

Outperform

Reason

Evercore ISI raised the firm's price target on Icon to $240 from $170 and keeps an Outperform rating on the shares. The company provided a further set of data points that the cycle is inflecting, and while it may not be all smooth sailing from here, the above-expectations BtB in Q2 as well as revenue improvement should help provide a significant dose of comfort in the improving demand environment, the analyst tells investors in a research note. The firm added that this demand environment seems similarly broad-based to comments earlier this week, benefitting form stable pharma, improved biotech, higher cardio-metabolic, aided as well by Icon's share gains.

See All Ratings

Valuation Metrics

The current forward P/E ratio for ICON PLC (ICLR.O) is 13.75, compared to its 5-year average forward P/E of 19.14. For a more detailed relative valuation and DCF analysis to assess ICON PLC 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Undervalued

5Y Average PE

19.14

Current PE

13.75

Overvalued PE

23.14

Undervalued PE

15.14

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

14.09

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

16.96

Undervalued EV/EBITDA

11.22

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

2.42

Current PS

0.00

Overvalued PS

2.95

Undervalued PS

1.89